Immunocore Holdings plc
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-35.5M | $-51.1M | $-55.3M | $-52.5M | $-180.0M |
| Depreciation & Amortization | $3.1M | $4.2M | $4.1M | $5.3M | $7.6M |
| Depreciation | $3.3M | $4.2M | $4.1M | $5.3M | $7.6M |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $37.7M | $34.2M | $32.5M | $32.9M | $48.9M |
| Net Cash from Operating Activities | $-10.7M | $26.1M | $2.9M | $-49.2M | $-143.1M |
| Investing Activities | |||||
| Capital Expenditures | $4.3M | $5.2M | $5.4M | $2.2M | $1.4M |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-16.3M | $-355.1M | $-5.4M | $-2.2M | $-1.3M |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $12.4M | $343.9M | $34.3M | $145.4M | $288.2M |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | $-15.1M | $20.9M | $-2.5M | $-51.4M | $-144.5M |